UNSPSC 51162707: Cartasteine

This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E3N11DY0TA. European Medicines Agency schedules Cartasteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06148MIG. Cartasteine generally arises in the molecular formula C9H14N2O4S2.

UNSPSC 51162707 Cartasteine, a Commodity code, encompasses pharmaceutical products and medical supplies that state and local governments procure for community health, emergency response, and public health initiatives. Based on recent solicitations, the code captures purchases of naloxone (opioid overdose reversal medication) and drug deactivation systems for public health departments, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through state and local healthcare facilities. Issuing bodies include county health departments, state procurement offices administering cooperative purchasing alliances, and participating state and local government facilities across multiple jurisdictions. The scope spans both specialized emergency-response pharmaceuticals and broader OTC product lines, with vendors required to maintain FDA compliance, current Good Manufacturing Practices certification, and contractual relationships with authorized pharmaceutical wholesalers.

Recent activity shows geographic spread across Florida and the Upper Midwest, with representation from Minnesota's multistate cooperative purchasing network and subsidiary participating states. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; bidders were required to submit proposals by July 26, 2023, with shipping and delivery costs included. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. Both solicitations require vendors to demonstrate insurance coverage, drug-free workplace certification, and compliance with federal pharmaceutical regulations; MMCAP specifically weights price competitiveness at 75 percent of evaluation.